Original Publication Date: 1 October, 2015
Publication / Source: Future Oncology
Authors: Giuseppe Di Lorenzo & Guru Sonpavde
The mainstay of treatment for metastatic prostate cancer is androgen deprivation (ADT). Unfortunately, the response to this therapy is short term with a median duration of 18–24 months. Most men become resistant to hormonal treatment, developing castration-resistant prostate cancer (CRPC) .
Until 2004, clinicians were reluctant to treat metastatic CRPC with chemotherapy because historically used agents conferred marginal benefits and/or had substantial toxicities. Mitoxantrone plus daily oral corticosteroids conferred modest palliative benefits without extending survival [1,2]. A review of 26 trials evaluating chemotherapeutic agents was published in 1993 and revealed only an overall response rate of 8.7% and median survival of 6–10 months, with the combination of vinblastine and estramustine appearing somewhat more active .
Click here to view the full article in Future Oncology.